诊断学理论与实践 ›› 2017, Vol. 16 ›› Issue (06): 576-581.doi: 10.16150/j.1671-2870.2017.06.003
施仲伟
收稿日期:
2017-11-02
出版日期:
2017-12-25
发布日期:
2017-12-25
Received:
2017-11-02
Online:
2017-12-25
Published:
2017-12-25
中图分类号:
施仲伟. SPRINT试验诚信不足无力改变高血压治疗目标值[J]. 诊断学理论与实践, 2017, 16(06): 576-581.
[1] Cunningham RL.Mechanism and clinical aspects of chronic arterial hypertension[J]. Cal State J Med,1912, 10(7):303-305. [2] The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure[J]. Arch Intern Med,1988,148(5):1023-1038. [3] Mancia G, De Backer G, Dominiczak A, et al.2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology(ESC)[J]. J Hypertens,2007,25(6):1105-1187. [4] Mancia G, Fagard R, Narkiewicz K, et al.2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertens,2013,31(7):1281-1357. [5] James PA, Oparil S, Carter BL, et al.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA,2014,311(5):507-520. [6] 施仲伟. 我看JNC 8:没了名分成绝唱, 有些底气靠质量[M]//葛均波, 方唯一, 沈卫峰. 现代心脏病学进展2014. 1版. 上海: 复旦大学出版社,2014:45-47. [7] Qaseem A, Wilt TJ, Rich R, et al.Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher [8] Wright JT Jr, Fine LJ, Lackland DT, et al.Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view[J]. Ann Intern Med,2014,160(7):499-503. [9] Borden WB, Maddox TM, Tang F, et al.Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry[J]. J Am Coll Cardiol,2014,64(21):2196-2203. [10] Ambrosius WT, Sink KM, Foy CG, et al.The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial(SPRINT)[J]. Clin Trials,2014,11(5):532-546. [11] SPRINT Research Group, Wright JT Jr, Williamson JD, et al.A Randomized Trial of Intensive [12] Verdecchia P, Angeli F, Reboldi G.The SPRINT trial[J]. J Am Soc Hypertens,2015,9(10):750-753. [13] National Institutes of Health. Landmark NIH study shows intensive blood pressure management may save lives: lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults[R].2017-10-26[2017-11-02].https://www.nih.gov/news-events/news-releases/landmark-nih-study-shows-intensive-blood-pressure-mana-gement-may-save-lives. [14] Williamson JD, Supiano MA, Applegate WB, et al.Intensive [15] Phillips RA.Current and future treatment of hypertension in the SPRINT Era[J]. Methodist Debakey Cardiovasc J,2015,11(4):206-213. [16] Tsioufis C, Tousoulis D.SPRINT Results Are Life-Saving, Guideline-Changing, and Hypertension Research-Intensifying[J]. Hellenic J Cardiol,2015,56(6):529-530. [17] Leung AA, Daskalopoulou SS, Dasgupta K, et al.Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults[J]. Can J Cardiol,2017,33(5):557-576. [18] Gabb GM, Mangoni AA, Anderson CS, et al.Guideline for the diagnosis and management of hypertension in adults-2016[J]. Med J Aust,2016,205(2):85-89. [19] Fuster V.No Such thing as ideal blood pressure: A case for personalized medicine[J]. J Am Coll Cardiol,2016,67(25):3014-3015. [20] Filippone EJ, Foy AJ.Blood pressure management in the wake of SPRINT[J]. Cleve Clin J Med,2016,83(3):196-198. [21] Esler M.SPRINT, or False Start, Toward a lower universal treated blood pressure target in hypertension[J]. Hypertension,2016,67(2):266-267. [22] Franklin SS, Jacobs MJ, Wong ND, et al.Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey(NHANES) Ⅲ[J]. Hypertension,2001,37(3):869-874. [23] Thomopoulos C, Parati G, Zanchetti A.Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials[J]. J Hypertens,2014,32(12):2285-2295. [24] Kjeldsen SE, Narkiewicz K, Hedner T, et al.The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg[J]. Blood Press,2016,25(2):63-66. [25] Lonn EM, Yusuf S.Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mmHg target? An antagonist view from the HOPE-3 Trial(Heart Outcomes Evaluation-3)[J]. Circulation,2016,134(18):1311-1313. [26] Myers MG, Godwin M, Dawes M, et al.Measurement of blood pressure in the office: recognizing the problem and proposing the solution[J]. Hypertension,2010,55(2):195-200. [27] Kjeldsen SE, Lund-Johansen P, Nilsson PM, et al.Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials[J]. Hypertension,2016,67(5):808-812. [28] Myers MG, Campbell NR.Unfounded concerns about the use of automated office blood pressure measurement in SPRINT[J]. J Am Soc Hypertens,2016,10(12):903-905. [29] Bundy JD, Li C, Stuchlik P, et al.Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-analysis[J]. JAMA Cardiol,2017,2(7):775-781. [30] Tsai WC, Wu HY, Peng YS, et al.Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: A systematic review and meta-analysis[J]. JAMA Intern Med,2017,177(6):792-799. [31] Bakris GL.The Implications of blood pressure measurement methods on treatment targets for blood pressure[J]. Circulation,2016,134(13):904-905. [32] Bakris G.Response by Bakris to letter regarding article, "The implications of blood pressure measurement metho-ds on treatment targets for blood pressure"[J]. Circulation,2017,135(7):e47. [33] Cushman WC, Whelton PK, Fine LJ, et al.SPRINT Trial results: Latest news in hypertension management[J]. Hypertension,2016,67(2):263-265. [34] Cushman WC, Evans GW, Rodriguez CJ, et al.Blood pressure intervention and control in the systolic blood pressure intervention trial (SPRINT)[J]. J Am Soc Hypertens,2016,10(4S):e4. [35] Myers MG, Valdivieso M, Kiss A.Use of automated office blood pressure measurement to reduce the white coat response[J]. J Hypertens,2009,27(2):280-286. [36] Agarwal R. Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial(SPRINT)[J]. J Am Heart Assoc,2017,6(2),pii:e004536. [37] Filipovsky J, Seidlerová J, Kratochvíl Z, et al.Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients[J]. Blood Press,2016,25(4):228-234. [38] 施仲伟. 美国胆固醇指南和高血压指南批评声音略显嘈杂[J]. 诊断学理论与实践,2014,13(1):39-43. [39] Schiffrin EL, Calhoun DA, Flack JM.Do We Need a New Definition of Hypertension After SPRINT?[J]. Am J Hypertens,2016,29(10):1127-1129. [40] ACCORD Study Group, Cushman WC, Evans GW, et al.Effects of intensive blood-pressure control in type 2 diabetes mellitus[J]. N Engl J Med,2010,362(17):1575-1585. [41] Lonn EM, Bosch J, López-Jaramillo P, et al.Blood-Pressure lowering in intermediate-risk persons without cardiovascular disease[J]. N Engl J Med,2016,374(21):2009-2020. [42] Elgendy IY, Bavry AA, Gong Y, et al.Long-term mortality in hypertensive patients with coronary artery disease: Results from the US Cohort of the International Verapamil (SR)/Trandolapril Study[J]. Hypertension,2016,68(5):1110-1114. [43] Mancia G, Kjeldsen SE, Zappe DH, et al.Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial[J]. Eur Heart J,2016,37(12):955-964. [44] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志,2011,39(7):579-616. |
[1] | 何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚. LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605. |
[2] | 陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430. |
[3] | 沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436. |
[4] | 陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534. |
[5] | 何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546. |
[6] | 徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊. 实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550. |
[7] | 赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394. |
[8] | 郭业兵, 郑金峰. 阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407. |
[9] | 王刚, 陈生弟. 神经病学的诊断:起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4. |
[10] | 唐静仪, 余群, 刘军. 结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17. |
[11] | 魏文石. 直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7. |
[12] | 王蔚, 王小钦. 缺铁性贫血的病因诊断[J]. 诊断学理论与实践, 2021, 20(06): 529-532. |
[13] | 岳婧婧, 宋琦, 江旭峰, 王黎, 赵维莅, 严福华. 磁共振全身扩散加权成像结合T2WI抑脂序列与FDG-PET/CT在初发淋巴瘤分期及病灶检出的对比研究[J]. 诊断学理论与实践, 2021, 20(06): 540-546. |
[14] | 王昭晖, 吴海波. 胃神经鞘瘤31例临床病理学分析[J]. 诊断学理论与实践, 2021, 20(06): 552-556. |
[15] | 王广宇, 杨昕, 张立娟, 谭姣容. 住院新诊断2型糖尿病男性患者血浆总睾酮水平与骨钙素的相关性研究[J]. 诊断学理论与实践, 2021, 20(06): 573-578. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||